Svas Biosana S p A : The Board of Directors of SVAS Biosana approves the short-form consolidated half-yearly financial statements as at 30 june 2023 -September 27, 2023 at 05:38 am EDT

EBITDA Margin 12.6%


Consolidated EBIT: €4.2 million - EBIT Margin 7.7%


Consolidated Net Profit: €2.3 million


...

Related Keywords

Milan ,Lombardia ,Italy ,Ukraine ,Slovenia ,Russia ,Bolzano ,Trentino Alto Adige ,Croatia ,Serbia ,Somma Vesuviana ,Campania ,Santagostino ,Emilia Romagna ,San Giuseppe Vesuviano ,Trentola ,Rome ,Lazio ,Italian ,Russian ,Ukrainian ,Umberto Perillo ,Borsa Italiana ,Banca Profilo ,Andrea Efficace ,Svas Biosana ,Sves Biosana ,Svas Biosana Group ,Ministry Of Health ,Bormia Group ,Companies Register ,Group Net Financial Position ,Development Department ,Investor Relations Press ,Ministry Of Economy ,National Health Fund ,Net Profit ,Net Financial Position ,Euronext Growth Milan ,Giuseppe Vesuviano ,Farmex Business Unit ,Mark Medical Business Unit ,Eastern Europe ,Gross Operating Margin ,Operating Profit ,Aiuti Bis Decree ,Decree Law ,Official Journal ,Medical Device Payback ,Italian Government ,Civil Code ,Mark Medical ,Euronext Growth Milan Issuer Regulations ,Press Releases ,Investor Relations Manager ,Markets ,